Insider Selling: Insulet Co. (NASDAQ:PODD) Director Sells 1,825 Shares of Stock

Insulet Co. (NASDAQ:PODD) Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company’s stock, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Insulet Stock Performance

PODD stock traded down $7.83 during trading on Wednesday, hitting $264.88. 948,765 shares of the company’s stock traded hands, compared to its average volume of 691,092. The stock has a fifty day moving average price of $272.27 and a two-hundred day moving average price of $258.19. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The stock has a market capitalization of $18.60 billion, a price-to-earnings ratio of 45.75, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, equities analysts anticipate that Insulet Co. will post 3.92 EPS for the current fiscal year.

Institutional Trading of Insulet

Hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new position in Insulet during the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new stake in Insulet in the 4th quarter valued at about $42,000. SRS Capital Advisors Inc. lifted its holdings in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 56 shares during the last quarter. Friedenthal Financial bought a new position in shares of Insulet during the 4th quarter valued at about $57,000. Finally, TD Private Client Wealth LLC grew its stake in shares of Insulet by 32.6% in the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. TD Cowen lifted their price objective on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Wells Fargo & Company boosted their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Citigroup boosted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Finally, Raymond James restated an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.